• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Frequency of procedural and medical treatments of actinic keratosis.

作者信息

Ranpariya Varun K, Muddasani Suraj, Mahon Andrew B, Feldman Steven R

机构信息

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

PHD Biosciences.

出版信息

J Am Acad Dermatol. 2022 Apr;86(4):916-918. doi: 10.1016/j.jaad.2021.03.047. Epub 2021 Mar 20.

DOI:10.1016/j.jaad.2021.03.047
PMID:33757796
Abstract
摘要

相似文献

1
Frequency of procedural and medical treatments of actinic keratosis.光化性角化病的手术及药物治疗频率
J Am Acad Dermatol. 2022 Apr;86(4):916-918. doi: 10.1016/j.jaad.2021.03.047. Epub 2021 Mar 20.
2
Actinic keratosis and imiquimod: a review of novel carriers and patents.光化性角化病和咪喹莫特：新型载体和专利的综述。
Expert Opin Drug Deliv. 2019 Feb;16(2):101-112. doi: 10.1080/17425247.2019.1560418. Epub 2018 Dec 24.
3
Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.0.025%和0.05%鬼臼毒素丁酯凝胶治疗光化性角化病的随机、双盲、双模拟、赋形剂对照研究
J Am Acad Dermatol. 2009 Jun;60(6):934-43. doi: 10.1016/j.jaad.2009.01.008.
4
Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis.了解光化性角化病的定向治疗研究中的疗效终点。
Int J Dermatol. 2013 Sep;52(9):1063-70. doi: 10.1111/j.1365-4632.2012.05776.x.
5
Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.局部应用咪喹莫特治疗结膜光化性角化病。
Ophthalmic Plast Reconstr Surg. 2017 Jan/Feb;33(1):e21-e23. doi: 10.1097/IOP.0000000000000432.
6
Retinoids for prevention and treatment of actinic keratosis.维甲酸用于光化性角化病的预防和治疗。
An Bras Dermatol. 2013 Jul-Aug;88(4):585-93. doi: 10.1590/abd1806-4841.20131803.
7
Case-based experience in the use of 5-fluorouracil cream 0.5% as monotherapy and in conjunction with glycolic acid peels for the treatment of actinic keratosis.基于病例的使用0.5% 5-氟尿嘧啶乳膏单药治疗以及联合乙醇酸换肤治疗光化性角化病的经验。
J Cosmet Laser Ther. 2010 Feb;12(1):42-6. doi: 10.3109/14764170903480005.
8
MAL Daylight Photodynamic Therapy for Actinic Keratosis: Clinical and Imaging Evaluation by 3D Camera.日光动力疗法治疗光化性角化病：三维相机的临床及影像学评估
Int J Mol Sci. 2016 Jul 11;17(7):1108. doi: 10.3390/ijms17071108.
9
Comparative study of trichloroacetic acid vs. photodynamic therapy with topical 5-aminolevulinic acid for actinic keratosis of the scalp.三氯乙酸与外用5-氨基酮戊酸光动力疗法治疗头皮光化性角化病的对比研究
Photodermatol Photoimmunol Photomed. 2015 Sep;31(5):233-8. doi: 10.1111/phpp.12164. Epub 2015 Feb 19.
10
In vivo Confocal Laser Microscopy for monitoring of actinic keratosis treatment: a comparison with histopathologic assessment after treatment with topical 5% 5-fluorouracil.体内共聚焦激光显微镜在光化性角化病治疗监测中的应用：与外用 5% 5-氟尿嘧啶治疗后组织病理学评估的比较。
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1155-1163. doi: 10.1111/jdv.14716. Epub 2018 Jan 23.

引用本文的文献

1
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment.光化性角化病的局部药物治疗：聚焦于1%替拉替林软膏
Dermatol Pract Concept. 2024 Jul 1;14(3 S1):e2024145S. doi: 10.5826/dpc.1403S1a145S.
2
Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis.光化性角化病患者拒绝外用5-氟尿嘧啶再治疗的定性分析
JMIR Dermatol. 2023 Feb 15;6:e39988. doi: 10.2196/39988.
3
Reasons for Patient Call-backs while being Treated with Topical 5-fluorouracil: A Retrospective Chart Review.
外用5-氟尿嘧啶治疗期间患者回访的原因：一项回顾性病历审查
J Clin Aesthet Dermatol. 2023 Jun;16(6):53-54.
4
Profile of Tirbanibulin for the Treatment of Actinic Keratosis.替拉瑞林治疗光化性角化病的概况
J Clin Aesthet Dermatol. 2022 Oct;15(10 Suppl 1):S3-S10.
5
Infrequent Follow-Up for Actinic Keratosis Treatment: A National Ambulatory Medical Care Survey.光化性角化病治疗的随访不频繁：一项全国门诊医疗护理调查。
J Clin Aesthet Dermatol. 2022 Jun;15(6):65-67.